This review summarises data that support the use of the fixed-dose combination bronchodilator tiotropium bromide monohydrate/olodaterol hydrochloride (Spiolto® Respimat®), hereafter referred to as tiotropium/olodaterol, in the treatment of chronic obstructive pulmonary disease (COPD). Also discussed is evidence favouring earlier treatment of COPD and the role of bronchodilators in this clinical setting. In Australia, tiotropium/olodaterol is registered with the Therapeutic Goods Administration (TGA) and is listed on the Pharmaceutical Benefits Scheme (PBS).
Independent commentary has been provided by Dr. Christopher Worsnop, a respiratory and sleep physician at the Austin and Northern Hospitals in Melbourne.
Please login below to download this issue (PDF)